SCHEMBL1290104

SCHEMBL1290104

CCOC(=O)c1cc(C2CC2)c2c(C)c(-c3ccc(N)c(F)c3)c(F)cn2c1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.36
HPGD P15428 5/20 0.36
GAA P10253 5/20 0.36
ALDH1A1 P00352 5/20 0.36
GLA P06280 4/20 0.36
PKM P14618 1/20 0.34
MAPT P10636 3/20 0.33
LMNA P02545 1/20 0.33
BRAF P15056 1/20 0.33
NPC1 O15118 4/20 0.33
RAB9A P51151 2/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TP53 P04637 2/20 0.33
POLB P06746 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
ATM Q13315 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
HSD17B10 Q99714 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1289979 0.91 GAA (0.39) KDM4EHPGDGAAALDH1A1GLA
SCHEMBL1290073 0.89 SMN1; SMN2 (0.42) KDM4EHPGDGAAALDH1A1GLA
SCHEMBL12501961 0.88 KDM4E (0.38) KDM4EHPGDGAAALDH1A1GLA
SCHEMBL1289943 0.88 TOP2A (0.34) KDM4EKMT2A
SCHEMBL1289972 0.88 KDM4E (0.36) KDM4EHPGDGAAALDH1A1GLA
SCHEMBL12502390 0.87 ALOX5AP (0.38) KDM4EHPGDGAAALDH1A1GLA
SCHEMBL1290245 0.86 KDM4E (0.34) KDM4EHPGDGAAALDH1A1GLA
Potassium Ion SCHEMBL1290141 0.86
SCHEMBL5421668 0.86 KDM4E (0.38) KDM4EHPGDGAAALDH1A1GLA
SCHEMBL12502207 0.85 CDK5 (0.42) KDM4EHPGDGAAALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3476844-B1 ANTIMICROBIAL 4-OXOQUINOLIZINES EMERGENT PRODUCT DEV GAITHERSBURG INC (US) 2020-11-11 EP disclosed
EP-3476844-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES Emergent Product Development Gaithersburg Inc. (US) 2019-05-01 EP disclosed
US-20190105367-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2019-04-11 US disclosed
US-10155021-B2 Antimicrobial 4-oxoquinolizines EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2018-12-18 US disclosed
US-20180296555-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. 2018-10-18 US disclosed
EP-2621491-B1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EMERGENT PRODUCT DEV GAITHERSBURG INC (US) 2018-08-29 EP disclosed
EP-3312176-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES Emergent Product Development Gaithersburg Inc. (US) 2018-04-25 EP disclosed
EP-2670410-B1 ANTIMICROBIAL 4-OXOQUINOLIZINES EMERGENT PRODUCT DEV GAITHERSBURG INC (US) 2017-12-20 EP disclosed
US-20170232060-A9 ANTIMICROBIAL 4-OXOQUINOLIZINES EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. 2017-08-17 US disclosed
US-20170209437-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EVOLVA SA (CH) 2017-07-27 US disclosed
US-8962842-B2 2-pyridone antimicrobial compositions EVOLVA SA (CH) 2015-02-24 US disclosed
EP-2670410-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES Evolva SA (CH) 2013-12-11 EP disclosed
US-20130252882-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES EVOLVA SA (CH) 2013-09-26 US disclosed
US-20130245035-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EVOLVA SA (CH) 2013-09-19 US disclosed
US-20130245035-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EVOLVA SA (CH) 2013-09-19 US disclosed
US-20130245035-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EVOLVA SA (CH) 2013-09-19 US disclosed
EP-2621491-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS Evolva SA (CH) 2013-08-07 EP disclosed
WO-2012104305-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES EVOLVA SA (CH) 2012-08-09 WO disclosed
WO-2012047487-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EVOLVA SA (CH) 2012-04-12 WO disclosed
WO-2012047487-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EVOLVA SA (CH) 2012-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190105367-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES CUL4A, DCAF15, CUL4B KDM4E 555/4885HPGD 1304/4885GAA 2095/4885
US-10155021-B2 Antimicrobial 4-oxoquinolizines DCAF15, CUL4A, CUL4B KDM4E 518/4885HPGD 1433/4885GAA 2043/4885
US-20180296555-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS TOP2A, TOP1, TOP2B KDM4E 1923/4885HPGD 553/4885GAA 2833/4885
US-20170232060-A9 ANTIMICROBIAL 4-OXOQUINOLIZINES CUL4A, DCAF15, CUL4B KDM4E 555/4885HPGD 1304/4885GAA 2095/4885
US-20130252882-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES CUL4A, DCAF15, CUL4B KDM4E 555/4885HPGD 1304/4885GAA 2095/4885
US-20130245035-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS TOP2A, TOP1, TOP2B KDM4E 2480/4885HPGD 766/4885GAA 2757/4885
US-20170209437-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS TOP2A, TOP1, TOP2B KDM4E 1923/4885HPGD 553/4885GAA 2833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.